IL2 and cancer: For future studies, it would be interesting to compare N-803 to the standard IL-2 co-administration with NK cell adoptive transfer for anti-tumor efficacy, to evaluate whether IL-2 can be replaced by N-803 to prevent Treg-expansion in cancer patients.